[HTML][HTML] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
O Merimsky, CK Cheng, JSK Au… - Oncology …, 2012 - spandidos-publications.com
Abstract Tarceva Lung cancer Survival Treatment (TRUST) was an open-label, phase IV
study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
[PDF][PDF] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
O MERIMSKY, CHIKIN CHENG… - ONCOLOGY …, 2012 - scholar.archive.org
TaRceva LUng cancer Survival Treatment (TRUST) was an open-label, phase IV study of
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
O MERIMSKY, CHIKIN CHENG, JSIUKIE AU… - Oncology …, 2012 - search.proquest.com
Abstract TaRceva LUng cancer Survival Treatment (TRUST) was an open-label, phase IV
study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
O Merimsky, CK Cheng, JS Au, J von Pawel… - Oncology …, 2012 - europepmc.org
TaRceva LUng cancer Survival Treatment (TRUST) was an open-label, phase IV study of
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
[引用][C] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
O MERIMSKY, CK CHENG, J SIU-KIE AU… - Oncology …, 2012 - pascal-francis.inist.fr
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung
cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
[HTML][HTML] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
O Merimsky, CK Cheng, JSK Au… - Oncology …, 2012 - spandidos-publications.com
Abstract Tarceva Lung cancer Survival Treatment (TRUST) was an open-label, phase IV
study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
[PDF][PDF] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
O MERIMSKY, CHIKIN CHENG, JSIUKIE AU… - ONCOLOGY …, 2012 - researchgate.net
TaRceva LUng cancer Survival Treatment (TRUST) was an open-label, phase IV study of
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
O Merimsky, CK Cheng, JSK Au… - Oncology …, 2012 - pubmed.ncbi.nlm.nih.gov
TaRceva LUng cancer Survival Treatment (TRUST) was an open-label, phase IV study of
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
O MERIMSKY, CHIKIN CHENG… - ONCOLOGY …, 2012 - ingentaconnect.com
Tarceva Lung cancer Survival Treatment (TRUST) was an open-label, phase IV study of
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …
advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …